The Impact of Artificial Intelligence-Derived Assessment of Natural and Built Environments on Cardiovascular Risk: A Moderated Mediation and Geospatial Analysis from the UK Biobank
Abstract Body (Do not enter title and authors here): Background Artificial Intelligence (AI) applied to high-resolution imagery offers a novel, scalable approach to comprehensively characterize nuanced environmental exposures. A growing body of evidence implicates the built and natural environment in atherosclerotic cardiovascular disease (ASCVD) risk. Hypothesis We hypothesized that a proportion of observed ASCVD events attributable to AI-derived geospatial features from the natural and built environment is mediated by traditional risk factors and moderated by underlying genetic susceptibility. Methods Individual-level data from the UK (n > 502,000, UKB) and the US Mass General Brigham (n > 144,000, MGB) biobanks served as training/test and validation cohorts, respectively. Using convolutional neural networks (CNNs), > 8,000 natural and built environment features extracted from Google Satellite Images (GSI) and Street Views (GSV) were used to derive cross-validated sparse partial least squares personalized geospatial GSI/GSV scores. Associations between these scores with MACE and key risk factors (LDL-C, BMI, SBP, T2DM) were modeled by multivariate Cox PH models, adjusted for demographics, clinical, and area-level socioeconomic status covariates. Polygenic Risk Score (PRS) moderation and causal mediation analyses were performed along with geospatial mapping. Results Out of 7 GSI and 4 GSV derived scores, 10 were significantly associated with MACE (all p < 0.001), with hazard ratios ranging from 0.961 to 1.048, comparable in magnitude to social deprivation and air pollution measures in UKB. Adding GSI/GSV scores to traditional risk models combining demographics, socio-determinants of health, and risk factors significantly improved model fit (GSI: likelihood ratio test (LRT) = 279.3, p < 0.001; GSV: LRT = 99.3, p < 0.001). Findings were validated in the MGB cohort for 4 of 7 GSI and 2 of 4 GSV features. Significant interaction effects were observed between GSI/GSV and PRS for LDL-C (p = 0.007), BMI (p = 0.05), and T2DM (p = 0.013). Causal mediation analysis revealed significant indirect effects and mediated proportions of GSI/GSV on SBP (p < 0.0001; 0.7%), T2DM (p < 0.0001; 0.5%), and BMI (p < 0.0001; 9.7%). Conclusion AI-derived environmental geospatial features are associated with ASCVD risk, partially mediated by traditional risk factors, while moderated by genetic susceptibility. These findings highlight the potential for scalable environmental risk modeling to advance precision cardiovascular prevention.
Dazard, Jean-eudes
( Case Western Reserve University
, Cleveland
, Ohio
, United States
)
Rajagopalan, Sanjay
( Case Medical Center
, Cleveland
, Ohio
, United States
)
Chen, Zhuo
( Case Western Reserve University
, Copley
, Ohio
, United States
)
Koyama, Satoshi
( Broad Institute
, Cambridge
, Massachusetts
, United States
)
Zhang, Tong
( Case Western Reserve University
, Cleveland
, Ohio
, United States
)
Ponnana, Sai Rahul
( Case Western Reserve University
, Cleveland
, Ohio
, United States
)
Sirasapalli, Santosh
( Case Western Reserve University
, Cleveland
, Ohio
, United States
)
Moorthy, Skanda
( Case Western Reserve University
, Cleveland
, Ohio
, United States
)
Al-kindi, Sadeer
( Houston Methodist
, Houston
, Texas
, United States
)
Natarajan, Pradeep
( Massachusetts General Hospital
, Brookline
, Massachusetts
, United States
)
Author Disclosures:
Jean-Eudes Dazard:DO NOT have relevant financial relationships
| Sanjay Rajagopalan:No Answer
| Zhuo Chen:DO NOT have relevant financial relationships
| Satoshi Koyama:DO NOT have relevant financial relationships
| Tong Zhang:DO NOT have relevant financial relationships
| Sai Rahul Ponnana:DO NOT have relevant financial relationships
| Santosh Sirasapalli:No Answer
| Skanda Moorthy:DO NOT have relevant financial relationships
| Sadeer Al-Kindi:DO have relevant financial relationships
;
Research Funding (PI or named investigator):Ionis Pharmaceuticals:Active (exists now)
| Pradeep Natarajan:DO have relevant financial relationships
;
Researcher:Amgen, Genentech / Roche:Active (exists now)
; Other (please indicate in the box next to the company name):Vertex Pharmaceuticals (spousal employment):Active (exists now)
; Ownership Interest:Bolt, Candela, Mercury, MyOme, Parameter Health, Preciseli, TenSixteen Bio:Active (exists now)
; Consultant:Allelica, CRISPR Therapeutics, Genentech/Roche, HeartFlow, Magnet Biomedicine:Past (completed)
; Consultant:AstraZeneca, Blackstone Life Sciences, Bristol Myers Squibb, Eli Lilly & Co, Esperion Therapeutics, Foresite Capital, Foresite Labs, GV, Merck, Novartis, Novo Nordisk, TenSixteen Bio, Tourmaline Bio:Active (exists now)
; Researcher:Allelica, Novartis:Past (completed)